Abstract

The present specification provides an antisense oligomer, or a pharmaceutically acceptable salt thereof, or a hydrate of the antisense oligomer or the salt having a length of 15 to 30 bases, comprising a base sequence complementary to a base sequence in a target region, wherein the target region comprises a sequence of at least 10 consecutive bases in at least one region selected from the group consisting of a 5′ UTR region, a nsp1 region, a nsp10 region, an RNA-dependent RNA polymerase region, an ORF10 region, and a 3′ UTR region in the genome RNA of SARS-CoV-2, or a complementary sequence thereof, wherein the antisense oligomer, or the pharmaceutically acceptable salt thereof, or the hydrate of the antisense oligomer or the salt has an antiviral effect on a virus selected from the group consisting of SARS-CoV-2, SARS-CoV-1, and MERS-CoV.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61P 31/14 - Antivirals for RNA viruses

Abstract

Provided are: a stretched film made of ultrahigh-molecular-weight polyethylene, the stretched film including ultrahigh-molecular-weight polyethylene having a weight-average molecular weight, as estimated from a molecular-weight distribution curve of the contained polyethylenes obtained by gel permeation chromatography, of 500,000 or higher in an amount of 90 mass% or larger with respect to the whole mass of the stretched film made of ultrahigh-molecular-weight polyethylene, and having a tensile rupture strength of 300 MPa or higher and an elongation at rupture of 7% or higher; and a method for producing a stretched film made of a polyolefin.

IPC Classes  ?

• C08J 5/18 - Manufacture of films or sheets
• B29C 55/02 - Shaping by stretching, e.g. drawing through a dieApparatus therefor of plates or sheets
• C08F 2/00 - Processes of polymerisation
• C08F 4/60 - MetalsMetal hydridesMetallo-organic compoundsUse thereof as catalyst precursors selected from light metals, zinc, cadmium, mercury, copper, silver, gold, boron, gallium, indium, thallium, rare earths, or actinides together with refractory metals, iron group metals, platinum group metals, manganese, technetium, rhenium, or compounds thereof
• C08F 10/00 - Homopolymers or copolymers of unsaturated aliphatic hydrocarbons having only one carbon-to-carbon double bond

Abstract

The present invention provides: a carbon catalyst which has both high catalytic activity and high durability; an electrode; and a battery. The carbon catalyst has an L/La ratio of 18 or more, the L/La ratio being the ratio of the average carbon mesh surface size L, which is obtained by programmed-temperature desorption analysis in which the temperature can be increased to 1600°C, to the crystallite size La, which is obtained from a diffraction peak near a diffraction angle (2θ) of 43° in an X-ray diffraction pattern obtained by means of powder X-ray diffraction using a CuKα ray, and a ratio of the halogen atom concentration (atom%) to the carbon atom concentration (atom%) of 0.0005 or more as obtained by X-ray photoelectron spectroscopy.

IPC Classes  ?

• H01M 4/96 - Carbon-based electrodes
• B01J 27/24 - Nitrogen compounds
• B01J 35/60 - Catalysts, in general, characterised by their form or physical properties characterised by their surface properties or porosity
• C25B 11/052 - Electrodes comprising one or more electrocatalytic coatings on a substrate
• C25B 11/075 - Electrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material consisting of a single catalytic element or catalytic compound
• C25B 11/091 - Electrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material consisting of at least one catalytic element and at least one catalytic compoundElectrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material consisting of two or more catalytic elements or catalytic compounds
• H01M 8/10 - Fuel cells with solid electrolytes
• H01M 12/06 - Hybrid cellsManufacture thereof composed of a half-cell of the fuel-cell type and of a half-cell of the primary-cell type with one metallic and one gaseous electrode
• H01M 12/08 - Hybrid cellsManufacture thereof composed of a half-cell of a fuel-cell type and a half-cell of the secondary-cell type

Abstract

The present invention provides a vascular smooth muscle cell-tropic capsid which has an enhanced rate of infection to a vascular smooth muscle.　The present invention provides a capsid of an adeno-associated virus, the capsid being characterized in that a factor of tropism for vascular smooth muscle cells is added thereto. The factor of tropism is a peptide that is presented on the surface of a virus particle.　The peptide includes any one of "RENKLGE", "KDTVPRE", "TETGKTA", "STPAAKE", "RNREPTE", "ARNGTTE", "KDTAERQ", "NRGGNQD", "NRPDTNS", and "TRATSQE" in cases where vascular smooth muscle cells of a mouse (Mus musculus) are to be infected. The peptide includes any one of "NRPETNP", "SHDPSKE", "SEIRRDQ", "NRNKHEE", "RQDNKME", "THPPAPQ", "TRGGGSE", "TEKQTNS", "RVTMGSE", and "ATKNQNE" in cases where vascular smooth muscle cells of human (Homo sapiens) are to be infected.

IPC Classes  ?

• C07K 14/015 - Parvoviridae, e.g. feline panleukopenia virus, human parvovirus
• A61K 35/76 - VirusesSubviral particlesBacteriophages
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 15/34 - Proteins from DNA viruses
• C12N 15/864 - Parvoviral vectors
• C12P 21/02 - Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione

Abstract

The present specification provides an antisense oligonucleotide or a pharmaceutically acceptable salt or hydrate thereof targeting a particular region in genomic RNA of SARS-CoV-2, a pharmaceutical composition comprising the antisense oligonucleotide or the pharmaceutically acceptable salt or hydrate thereof, etc.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

[Problem] To provide: a method for inexpensively producing a highly active oxygen carrier; a method for producing hydrogen using the highly active oxygen carrier; and an apparatus for producing hydrogen. [Solution] This method for producing an activated iron titanate-containing oxygen carrier which contains alkali titanate and iron oxide by firing a mixture of iron titanate particles and an alkali component is characterized in that the mixture of the iron titanate particles and the alkali component is prepared by physically mixing the iron titanate particles and an alkali compound, or by spraying or impregnating the iron titanate particles with an aqueous solution of the alkali compound and then drying the same.

IPC Classes  ?

• C01G 49/00 - Compounds of iron
• C01B 3/08 - Production of hydrogen or of gaseous mixtures containing hydrogen by reaction of inorganic compounds containing electro-positively bound hydrogen, e.g. water, acids, bases, ammonia, with inorganic reducing agents with metals

Abstract

A biodegradable resin composition is usable for producing a molded article having high biodegradability particularly in the ocean. The biodegradable resin composition contains a biodegradable resin and one or more components selected from agarose, sodium alginate, casein, and keratin. The content of the biodegradable resin is 50% by weight or more.

IPC Classes  ?

• C08L 67/04 - Polyesters derived from hydroxy carboxylic acids, e.g. lactones
• C08L 67/02 - Polyesters derived from dicarboxylic acids and dihydroxy compounds

Abstract

An object of the present invention is to provide an antiviral nucleic acid, etc. against SARS-COV-2 SARS-COV-2, SARS-COV-1, or MERS-COV and/or a method for treating and/or preventing viral infection using the nucleic acid, etc. The present invention relates to, for example, an antiviral nucleic acid or a pharmaceutically acceptable salt or hydrate thereof targeting a sequence in at least one target region selected from the group consisting of 5′ UTR region, nsp3 region, 3C-like proteinase region, nsp9 region, RNA-dependent RNA polymerase region, helicase region, 3′-to-5′ exonuclease region, 2′-O-ribose methyltransferase region, S region including S1 region and S2 region, E region, M region, and N region in genomic RNA of SARS-COV-2, wherein the virus is SARS-COV-2, SARS-COV-1, or MERS-COV.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 31/712 - Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
• A61K 31/7125 - Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• A61P 31/12 - Antivirals

Abstract

Provided are a carbon catalyst that exhibits high catalytic activity, an electrode, and a battery. The carbon catalyst has: a ratio L/La of at least 15, said L/La ratio being the ratio of the average carbon mesh surface size L, that was obtained by using temperature-programmed desorption analysis capable of raising the temperature to 1600°C, to the crystallite size La that was obtained from a diffraction peak near a diffraction angle (2θ) of 43° in an X-ray diffraction pattern obtained by means of powder X-ray diffraction using a CuKα ray; and a BET specific surface area of at least 100 m2/g.

IPC Classes  ?

• B01J 21/18 - Carbon
• B01J 35/60 - Catalysts, in general, characterised by their form or physical properties characterised by their surface properties or porosity
• B01J 35/77 - Compounds characterised by their crystallite size
• C25B 11/052 - Electrodes comprising one or more electrocatalytic coatings on a substrate
• C25B 11/075 - Electrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material consisting of a single catalytic element or catalytic compound
• H01M 4/90 - Selection of catalytic material
• H01M 8/10 - Fuel cells with solid electrolytes
• H01M 12/06 - Hybrid cellsManufacture thereof composed of a half-cell of the fuel-cell type and of a half-cell of the primary-cell type with one metallic and one gaseous electrode
• H01M 12/08 - Hybrid cellsManufacture thereof composed of a half-cell of a fuel-cell type and a half-cell of the secondary-cell type

Abstract

Provided are: a carbon catalyst which exhibits high catalytic activity while effectively avoiding problems attributable to iron; an electrode; and a battery. The carbon catalyst has an L/La of 12 or greater, wherein the La is a crystallite size obtained from a diffraction peak at a diffraction angle (2θ) of about 43° in an X-ray diffraction pattern obtained by X-ray powder diffractometry with CuKα line and the L is an average carbon sheet size obtained by thermal desorption spectrometry capable of heating to 1600°C. The carbon catalyst has an iron content of 3,000 ppm or less.

IPC Classes  ?

• B01J 21/18 - Carbon
• B01J 35/60 - Catalysts, in general, characterised by their form or physical properties characterised by their surface properties or porosity
• B01J 35/77 - Compounds characterised by their crystallite size
• C25B 11/052 - Electrodes comprising one or more electrocatalytic coatings on a substrate
• C25B 11/075 - Electrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material consisting of a single catalytic element or catalytic compound
• H01M 4/90 - Selection of catalytic material
• H01M 8/10 - Fuel cells with solid electrolytes
• H01M 12/06 - Hybrid cellsManufacture thereof composed of a half-cell of the fuel-cell type and of a half-cell of the primary-cell type with one metallic and one gaseous electrode
• H01M 12/08 - Hybrid cellsManufacture thereof composed of a half-cell of a fuel-cell type and a half-cell of the secondary-cell type

Abstract

The present invention is an estimation device (1) comprising an overvoltage calculation unit (20) for calculating the overvoltage of a battery (50) on the basis of a measured value for a current flowing through the battery (50) and a measured value for the terminal voltage of the battery (50), and an estimation unit (30) having a system identification unit and an effective resistance calculation unit, wherein the estimation device (1) is characterized in that the system identification unit identifies the system of the battery (50) by estimating the parameters of each term in a polynomial constituting an FIR model on the basis of time-series data pertaining to the current and the overvoltage, and the effective resistance calculation unit calculates the effective resistance on the basis of the system of the battery (50), the system identification unit dividing the polynomial constituting the FIR model into a plurality of time segments and estimating a common parameter with respect to the terms included in the respective time segments to thereby estimate a smaller number of parameters than the number of terms in the polynomial of the FIR model.

IPC Classes  ?

• G01R 31/367 - Software therefor, e.g. for battery testing using modelling or look-up tables
• G01R 31/3828 - Arrangements for monitoring battery or accumulator variables, e.g. SoC using current integration
• G01R 31/388 - Determining ampere-hour charge capacity or SoC involving voltage measurements
• G01R 31/389 - Measuring internal impedance, internal conductance or related variables
• H01M 10/48 - Accumulators combined with arrangements for measuring, testing or indicating the condition of cells, e.g. the level or density of the electrolyte
• H02J 7/00 - Circuit arrangements for charging or depolarising batteries or for supplying loads from batteries

Abstract

A novel drug for treating or preventing skin hardening in systemic scleroderma has been discovered due to the discovery that skin hardening in systemic scleroderma can be ameliorated by the administration of a sirolimus-containing topical drug to the skin.

IPC Classes  ?

• A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
• A61K 9/06 - OintmentsBases therefor
• A61K 9/08 - Solutions
• A61K 9/10 - DispersionsEmulsions
• A61K 9/70 - Web, sheet or filament bases
• A61P 17/00 - Drugs for dermatological disorders
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• C12N 15/12 - Genes encoding animal proteins
• C12N 15/28 - Tumor necrosis factors

Abstract

A promoter on an AAV vector was changed to an Iba1 promoter, and a configuration that combined a miR-9 complementary sequence (miR-9T) and a miR-129 complementary sequence (miR-129T) was adopted. An exogenous gene was clarified to be efficiently and specifically expressed in microglia by using this vector, resulting in that an AAV vector that could efficiently and specifically express an exogenous gene in microglia of the central nervous system, was found.

IPC Classes  ?

• C12N 15/86 - Viral vectors
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy

Abstract

Provided are an ultra-high molecular weight polyethylene sheet, and a method for producing a polyolefin sheet, the method comprising a step A for applying an organic solvent containing a metal catalyst to the inner wall surface of a container, and a step B for synthesizing polyolefin on the inner wall surface of the container by introducing an olefin monomer into the container in which the inner wall surface is coated with the organic solvent containing a metal catalyst, wherein in the step A, the organic solvent containing a metal catalyst is applied to the inner wall surface of the container by moving the container.

IPC Classes  ?

• C08F 2/00 - Processes of polymerisation
• C08F 10/00 - Homopolymers or copolymers of unsaturated aliphatic hydrocarbons having only one carbon-to-carbon double bond
• C08F 10/02 - Ethene
• C08J 5/18 - Manufacture of films or sheets

Abstract

An inhibitory neuron-specific promoter sequence is discovered, which has a shorter length compared with a mGAD65 promoter and is not deteriorated in all of a promoter activity, specificity to an inhibitory neuron and a gene expression efficiency. More specifically, a promoter is provided, which comprises DNA having a promoter activity, in which the DNA comprises a nucleotide sequence for a Dlx1 binding site and/or a Dlx2 binding site in a glutamic acid decarboxylase (GAD) promoter and a nucleotide sequence for a region lying between the 5'-terminal of exon 1 and a transcription start point (TSS) in a glutamic acid decarboxylase (GAD).

IPC Classes  ?

• C12N 15/864 - Parvoviral vectors
• A61K 35/76 - VirusesSubviral particlesBacteriophages
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 25/08 - AntiepilepticsAnticonvulsants
• A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C12N 7/01 - Viruses, e.g. bacteriophages, modified by introduction of foreign genetic material

Abstract

The present invention comprises: an introduction section that has a first solid-state device having a semiconductor quantum well structure, and into which a plurality of electron spin waves are introduced; a modulation section that has a second solid-state device having a semiconductor quantum well structure connected to the introduction section, and synthesizes the electron spin waves from the introduction section to generate multiple electron spin waves; and a separation section having a third solid-state device having a semiconductor quantum well structure connected to the modulation section, the multiple electron spin waves synthesized in the modulation section being introduced in the separation section, the separation section separating the plurality of electron spin waves from the multiple electron spin waves. The modulation section has the function of superposition of the plurality of electron spin waves by controlling the amplitude, phase, and polarization degrees of freedom of the electron spin waves using the permanent spin-swirling state in the crystal orientation dependence of the effective magnetic field due to spin-orbit interaction generated in the semiconductor quantum well structure.

IPC Classes  ?

• H04B 10/90 - Non-optical transmission systems, e.g. transmission systems employing non-photonic corpuscular radiation
• H04B 10/60 - Receivers

Abstract

In this magnetic levitation motor, an attraction force toward a one-side stator acts on a rotor, and an attraction force toward the other-side stator acts on the rotor, whereby the rotor is caused to levitate between the one-side stator and the other-side stator. Further, the rotor is rotated through control of supply of electric current to each winding of the other-side stator and control of the magnetic pole at the one-side surface of each salient pole of the other-side stator. Here, the one-side stator is provided with a permanent magnet, but is not provided with a winding. Thus, this motor can be provided by a simple configuration.

IPC Classes  ?

• H02K 21/24 - Synchronous motors having permanent magnetsSynchronous generators having permanent magnets with stationary armatures and rotating magnets with magnets axially facing the armatures, e.g. hub-type cycle dynamos
• H02K 7/09 - Structural association with bearings with magnetic bearings

Abstract

Provided is a motor control device capable of improving efficiency in real time by a neural network structure that directly derives, in a learning manner, an output signal providing optimal efficiency. A motor control device 1 is adapted to control a motor 6, and includes a neural network compensator 11 that receives input signals and repeats learning based on forward propagation and backpropagation thereby to derive an output signal providing optimal efficiency. Input signals are a motor current, a motor parameter and torque, and the like, and output signals are a current command value and a current phase command value. The motor 6 is controlled on the basis of an output signal derived by the neural network compensator 11.

IPC Classes  ?

• H02P 21/00 - Arrangements or methods for the control of electric machines by vector control, e.g. by control of field orientation
• H02P 21/13 - Observer control, e.g. using Luenberger observers or Kalman filters
• H02P 21/18 - Estimation of position or speed
• H02P 21/22 - Current control, e.g. using a current control loop
• G06N 3/084 - Backpropagation, e.g. using gradient descent

Abstract

The present specification provides an antisense oligomer that has a length of 15-30 bases and that has a base sequence complementary to the base sequence of a target region, a pharmaceutically acceptable salt thereof, or a hydrate of the same. The target region has: a base sequence that is consecutive by at least 10 times and that is in at least one region selected from the group consisting of the 5' UTR region, the nsp1 region, the nsp10 region, the RNA-dependent RNA polymerase region, the ORF10 region, and the 3' UTR region in the genome RNA of SARS-CoV-2; or a sequence complementary to said base sequence. The antisense oligomer, or the pharmaceutically acceptable salt thereof, or the hydrate of the same has an antiviral effect with respect to a virus selected from the group consisting of SARS-CoV-2, SARS-CoV-1, and MERS-CoV.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61K 31/7125 - Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
• A61K 31/787 - Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 31/12 - Antivirals
• C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical

Abstract

Fucosylated α1-acid glycoprotein (fAGP) was found to be useful for the diagnosis of pancreatic cancer and malignant intraductal papillary mucinous neoplasm (IPMC), resulting in the finding of a new biomarker for pancreatic cancer or malignant intraductal papillary mucinous neoplasm (IPMC), in particular, a new biomarker useful for rapid diagnosis of malignant intraductal papillary mucinous neoplasm (IPMC) that increases the accuracy of malignant intraductal papillary mucinous neoplasm (IPMC) and aids conventional imaging diagnosis by making a suitable preoperative diagnosis of a benign neoplasm or a malignant neoplasm in intraductal papillary mucinous neoplasm (IPMN).

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals

Abstract

A blood measurement device (10) includes a light emitting part (11) that emits a light beam that is to transmit through a measurement site (18), a light receiving part (19) that receives the light beam that has transmitted through the measurement site (18), an integrating sphere part (14) interposed in an optical path along which the light beam emitted from the light emitting part (11) reaches the light receiving part (19), the integrating sphere part (14) having formed inside a reflection surface (26) that reflects the light beam, a light entry part (23) which is an opening provided at the integrating sphere part (14) and through which the light beam applied from the light emitting part (11) enters an inside of the integrating sphere part (14), and a light exit part (16) which is an opening provided at the integrating sphere part (14) and through which the light beam reflected by the reflection surface (26) of the integrating sphere part (14) is emitted from the integrating sphere part (14) toward the measurement site (18).

IPC Classes  ?

• A61B 5/1455 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using optical sensors, e.g. spectral photometrical oximeters
• A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value

Abstract

It is an object of the present invention to provide a therapeutic drug for carcinomatous peritonitis. According to the present invention, a therapeutic drug for carcinomatous peritonitis which comprises an antibody which recognizes a transferrin receptor, is provided.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61P 35/00 - Antineoplastic agents
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61P 1/18 - Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes

Abstract

Provided is a blood measurement device capable of accurately estimating the amount of a component contained in blood by passing light beams for calculating the amount of the component contained in blood along the same optical axis. A blood measurement device 10 of the present invention includes a light emitting part 11 having a first light emitting part 111 and a second light emitting part 112, a light receiving part 19, an actuator 16, and a computation and control part 17 that estimates a glucose level and controls operation of the actuator 16. When applicating a first light beam from the first light emitting part 111 to a measurement site, the computation and control part 17 causes the actuator 16 to move a light emission point of the first light emitting part 111 onto an optical axis 22 defined to penetrate through the measurement site, and when applicating a second light beam from the second light emitting part 112 to the measurement site, the computation and control part 17 causes the actuator 16 to move a light emission point of the second light emitting part 112 onto the optical axis 22.

IPC Classes  ?

• A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons

Abstract

The present invention addresses the problem of providing an antifungal eye drop, particularly, an aqueous eye drop, the eye drop containing luliconazole as an active ingredient. The problem is solved by the eye drop which contains: 1) luliconazole; 2) benzyl alcohol; and 3) one or two selected from polyoxyethylene polyoxypropylene glycol and polyoxyethylene hydrogenated castor oil.

IPC Classes  ?

• A61K 31/4178 - 1,3-Diazoles not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
• A61K 9/08 - Solutions
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61P 27/02 - Ophthalmic agents
• A61P 31/10 - Antimycotics

Abstract

Provided is a method for manufacturing an oligofuran skeleton-containing polycarbosilane, comprising a polymerization step in which a dihydro-silyl oligofuran compound is reacted with a diene compound and/or a diyne compound in the presence of a hydrosilylation catalyst, wherein the dihydro-silyl oligofuran compound is a compound in which both terminal furan rings of a 2 to 256-mer of a monofuran compound has a hydrosilyl group at the α-position thereof.

IPC Classes  ?

• C08G 77/60 - Macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing silicon, with or without sulfur, nitrogen, oxygen, or carbon in which all the silicon atoms are connected by linkages other than oxygen atoms

Abstract

A method for producing a dihydrosilyloligofuran compound, comprising a deprotonization step in which an oligofuran compound is deprotonized in the presence of a deprotonization agent and a silylation step in which the product of deprotonization of the oligofuran compound is reacted with a hydrosilane compound, the oligofuran compound being a dimer to 256-mer of a monofuran compound.

IPC Classes  ?

• C07F 7/08 - Compounds having one or more C—Si linkages

Abstract

The present invention addresses the problem of developing a fluorescent reagent with which lipid droplets from the scale of cultured cells to the scale of an individual can be imaged at high sensitivity, and which can be used in combination with a green fluorescent protein. The present invention provides a reagent for detecting lipid droplets, the reagent containing a compound represented by formula (I). (In the formula, m represents an integer of 3-5, n represents an integer of 3-5, and R represents a C1-5 alkyl, a C6-12 aryl, a C7-13 aralkyl, or hydrogen.)

IPC Classes  ?

• G01N 21/78 - Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator producing a change of colour
• A61K 49/00 - Preparations for testing in vivo
• C07D 405/04 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C09B 57/02 - Coumarine dyes
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G01N 33/92 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving lipids, e.g. cholesterol

Abstract

In the present description, provided are an antisense oligonucleotide targeting a specific region of the genomic RNA of SARS-CoV-2, a pharmaceutically acceptable salt thereof or a hydrate of the same, a pharmaceutical composition containing the antisense oligonucleotide, a pharmaceutically acceptable salt thereof or a hydrate of the same, etc.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 31/14 - Antivirals for RNA viruses

Abstract

By PCR using peptide nucleic acid (PNA), the present inventors have established a method for single nucleotide polymorphism examination including the detection of a missense mutation c.59T>G which is common in the recessive le allele of FUT3 gene (Le gene) possessed by Japanese people. Thus, the present inventors have successfully provided a rapid and simple method by which the presence or absence of the gene mutation participating in the sugar chain antigen production can be checked, in parallel with a CA19-9 test, at a clinical examination site.

IPC Classes  ?

• C12Q 1/686 - Polymerase chain reaction [PCR]
• C12Q 1/6858 - Allele-specific amplification
• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

An electrode for a redox flow battery, including a plate-shaped carbon electrode material, in which uniform consecutive macropores are formed in a three-dimensional network form and contact interface between carbon particles does not exist, in which: an average macropore diameter of the carbon electrode material is in a range of from 6 μm to 35 μm; an interplanar distance of (002) planes of a graphite crystallite in the carbon electrode material is in a range of from 0.33 nm to 0.40 nm; and a crystallite size of a graphite crystallite in a c-axis direction in the carbon electrode material is in a range of from 0.9 nm to 8.5 nm.

IPC Classes  ?

• H01M 4/583 - Carbonaceous material, e.g. graphite-intercalation compounds or CFx
• H01M 8/18 - Regenerative fuel cells, e.g. redox flow batteries or secondary fuel cells
• H01M 4/04 - Processes of manufacture in general
• H01M 4/36 - Selection of substances as active materials, active masses, active liquids

Abstract

An imaging device includes a varifocal lens and an imaging sensor which outputs a signal corresponding to light. The imaging sensor includes a photoelectric conversion unit which converts light into an electric charge, electric charge reading regions, transfer control electrodes, a gate control circuit which sequentially applies control signals to the transfer control electrodes to correspond to the position of the focal point of the varifocal lens, and a reading circuit which outputs a signal corresponding to the amount of the electric charge transferred to the electric charge reading regions. The gate control circuit repeats an operation of outputting each of the control signals when the position of the focal point is located in the focal ranges during a frame period.

IPC Classes  ?

• H04N 25/50 - Control of the SSIS exposure
• H04N 25/77 - Pixel circuitry, e.g. memories, A/D converters, pixel amplifiers, shared circuits or shared components
• G02B 7/28 - Systems for automatic generation of focusing signals
• H04N 13/236 - Image signal generators using stereoscopic image cameras using a single 2D image sensor using varifocal lenses or mirrors

Abstract

Provided are: a sub-micron thin film made of an ultra-high molecular weight polyethylene, the sub-micron thin film containing, as a main component, an ultra-high molecular weight polyethylene that has a viscosity average molecular weight of 1,000,000 to 15,000,000, and having a film thickness of less than 1 μm and a tensile strength at break of 100 MPa or higher; and a method for manufacturing the same.

IPC Classes  ?

• C08J 5/18 - Manufacture of films or sheets
• B29C 55/12 - Shaping by stretching, e.g. drawing through a dieApparatus therefor of plates or sheets multiaxial biaxial

Abstract

Provided is a composition for producing a parental-line animal/plant capable of producing and maintaining an epigenome-modified animal/plant.　A composition according to the present invention is employed in producing a parental-line animal/plant employed in producing or maintaining an epigenome-modified animal/plant, wherein: the composition contains nucleic acids; the nucleic acids contain nucleic acids coding for a nucleic-acid-sequence recognition module that specifically binds to a nucleic acid sequence in a target region, in which an epigenome modification is performed in a genomic DNA, and an epigenome modifying enzyme that is capable of modifying an epigenome; the sequence recognition module and the epigenome modifying enzyme can form a complex; the nucleic acids are configured so that, as a result of being functionally joined with a gametogenesis-specific promoter activated in a gametogenesis, the expressions of the sequence recognition module and the epigenome modifying enzyme are induced in the gametogenesis; and, in the gametogenesis, the nucleic-acid-sequence recognition module and the epigenome modifying enzyme, the expressions of which have been induced, form a complex and modify an epigenome in the target region in the genomic DNA of a gamete in the process of the gametogenesis.

IPC Classes  ?

• A01H 1/00 - Processes for modifying genotypes
• C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
• C07K 19/00 - Hybrid peptides
• C12N 5/075 - OocytesOogonia
• C12N 5/076 - Sperm cellsSpermatogonia
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 15/09 - Recombinant DNA-technology
• C12N 15/54 - Transferases (2)
• C12N 15/55 - Hydrolases (3)
• C12N 15/62 - DNA sequences coding for fusion proteins
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C12N 9/12 - Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
• C12N 9/16 - Hydrolases (3.) acting on ester bonds (3.1)
• A01K 67/027 - New or modified breeds of vertebrates

Abstract

Provided is a biodegradable resin composition that can be used particularly for the production of a molded article having high marine biodegradability. In particular, provided is a biodegradable resin composition which contains a biodegradable resin and one or more components selected from the group consisting of agarose, sodium alginate, casein, and keratin, and has a biodegradable resin content of 50 wt% or greater.

IPC Classes  ?

• C08L 101/00 - Compositions of unspecified macromolecular compounds
• C08L 67/00 - Compositions of polyesters obtained by reactions forming a carboxylic ester link in the main chainCompositions of derivatives of such polymers
• C08L 101/16 - Compositions of unspecified macromolecular compounds the macromolecular compounds being biodegradable

Abstract

The present invention addresses the problem of providing: an antiviral nucleic acid, etc., against SARS-CoV-2 SARS-CoV-2, SARS-CoV-1, or MERS-CoV; and/or a method for treating and/or preventing a viral infection using the nucleic acid, etc.　The present invention relates to an antiviral nucleic acid that targets a sequence in at least one target region selected from the group consisting of the 5' UTR region, nsp3 region, 3C-like proteinase region, nsp9 region, RNA-dependent RNA polymerase region, helicase region, 3'-to-5' exonuclease region, 2'-O-ribose methyltransferase region, S region including S1 region and S2 region, E region, M region, and N region in the genomic RNA of SARS-CoV-2, or a pharmacologically acceptable salt thereof or a hydrate of these, etc., wherein the virus is SARS-CoV-2, SARS-CoV-1, or MERS-CoV.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61K 31/712 - Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
• A61K 31/7125 - Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 31/12 - Antivirals
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression

Abstract

A volumetric display capable of high-speed image presentation includes a resonance-type liquid lens having a focal length that is periodically adjusted using resonance of a liquid. An image projector projects an image toward a viewpoint position of a user via the resonance-type liquid lens. Further, the image projector projects an image toward the viewpoint position within a shorter time period than one-tenth of a variation cycle of the focal length. The image projector includes an LED and a DMD, for example.

IPC Classes  ?

• G02B 30/50 - Optical systems or apparatus for producing three-dimensional [3D] effects, e.g. stereoscopic images the image being built up from image elements distributed over a 3D volume, e.g. voxels
• H04N 13/388 - Volumetric displays, i.e. systems where the image is built up from picture elements distributed through a volume
• H04N 13/365 - Image reproducers using digital micromirror devices [DMD]
• H04N 13/398 - Synchronisation thereofControl thereof
• G02F 1/29 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulatingNon-linear optics for the control of the position or the direction of light beams, i.e. deflection
• G02F 1/33 - Acousto-optical deflection devices
• G03B 21/00 - Projectors or projection-type viewersAccessories therefor
• G03B 21/20 - Lamp housings

Abstract

The present invention aims to develop a compound and a reagent having long phosphorescence lifetimes, for use in imaging of a hypoxic cell/tissue or for use in measurement/quantification of the oxygen concentration thereof. The present invention provides a reagent for measuring oxygen concentration, comprising a compound represented by the following General Formula (I) or (II). The present invention aims to develop a compound and a reagent having long phosphorescence lifetimes, for use in imaging of a hypoxic cell/tissue or for use in measurement/quantification of the oxygen concentration thereof. The present invention provides a reagent for measuring oxygen concentration, comprising a compound represented by the following General Formula (I) or (II). The present invention aims to develop a compound and a reagent having long phosphorescence lifetimes, for use in imaging of a hypoxic cell/tissue or for use in measurement/quantification of the oxygen concentration thereof. The present invention provides a reagent for measuring oxygen concentration, comprising a compound represented by the following General Formula (I) or (II). wherein R1 and R2 each independently represent hydrogen or a C1-C6 hydrocarbon group; and X− represents a counter anion.

IPC Classes  ?

• C07F 15/00 - Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
• A61K 49/00 - Preparations for testing in vivo
• G01N 21/64 - FluorescencePhosphorescence

Abstract

The present invention addresses the problem of developing a novel reagent for blood vessel imaging that is easy to produce, highly sensitive and highly accurate. The present invention provides a reagent for blood vessel imaging that contains a compound comprising an oligoarginine represented by formula and a phosphor or fluorophore group bound to the C-terminal or N-terminal side of the oligoarginine.

IPC Classes  ?

• A61K 49/00 - Preparations for testing in vivo
• C07F 15/00 - Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
• G01N 21/64 - FluorescencePhosphorescence

Abstract

The present invention addresses the problem of providing a recombinant antibody, a recombinant antibody derivative, or a drug composition including one or more of such antibodies which can be used to treat SARS-CoV2 virus infection by neutralizing infection by a SARS-CoV2 virus amplified inside the body due to a SARS-CoV2 virus infection.　As a result of rigorous examination, the inventors of the present invention have discovered a plurality of cells that produce antibodies against the SARS-CoV2 virus from bodies which have been infected with and recovered from the SARS-CoV2 virus in the past, and have shown that the aforementioned problem can be solved by making, from the aforementioned cells, antibodies or antibody derivatives that have the ability to bind to one or more SARS-CoV2 viruses and have the action of suppressing amplification of the SARS-CoV2 virus or neutralizing SARS-CoV2 virus infection.

IPC Classes  ?

• C12N 15/13 - Immunoglobulins
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 31/14 - Antivirals for RNA viruses
• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• C07K 16/46 - Hybrid immunoglobulins
• C12P 21/08 - Monoclonal antibodies

Abstract

B>1), thereby forming a more moderate electric field region. A reduced gold fine particle group (average particle size: 20 nm) was self-assembled on a transparent polyester resin film and half-submerged and fixed. This base material was repeatedly immersed in an electroless gold plating solution so that gold particles were deposited on the gold fine particles. 10 microliters of a protein solution was added dropwise to this nanostructured substrate, and crystallized by a hanging drop vapor diffusion method.

IPC Classes  ?

• C30B 29/58 - Macromolecular compounds
• B01J 19/12 - Processes employing the direct application of electric or wave energy, or particle radiationApparatus therefor employing electromagnetic waves
• C07K 1/30 - ExtractionSeparationPurification by precipitation
• C30B 7/00 - Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
• C30B 30/04 - Production of single crystals or homogeneous polycrystalline material with defined structure characterised by the action of electric or magnetic fields, wave energy or other specific physical conditions using magnetic fields
• B82Y 30/00 - Nanotechnology for materials or surface science, e.g. nanocomposites

Abstract

The present invention aims to provide a fluorescent reagent capable of highly sensitive imaging of a lipid droplet at a level ranging from cultured cells to individuals. A lipid droplet detection reagent including a compound represented by the following General Formula (I) is provided. 3; and y represents an integer of 0 to 5.

IPC Classes  ?

• C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
• G01N 21/64 - FluorescencePhosphorescence
• G01N 33/92 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving lipids, e.g. cholesterol

Abstract

Provided is a blood measurement device that is capable of accurately estimating blood component amounts, by causing each light ray for calculating blood component amounts to pass along the same optical axis.　This blood measurement device 10 comprises: a light-emission unit 11 that has a first light-emission unit 111 and a second light-emission unit 112; a light-reception unit 19; an actuator 16; and a calculation control unit 17 that estimates the amount of glucose and controls the operation of the actuator 16. In addition, the calculation control unit 17 moves, by using the actuator 16, the light-emission point for the first light-emission unit 111 onto an optical axis 22 that is defined so as to penetrate a measurement site, when irradiating the first light ray on to the measurement site from the first light-emission unit 111. The calculation control unit 17 also moves the light-emission point for the second light-emission unit 112 on to the optical axis 22, by using the actuator 16, when irradiating the second light ray on the measurement site from the second light-emission unit 112.

IPC Classes  ?

• G01N 21/359 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light using near infrared light
• A61B 5/1455 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using optical sensors, e.g. spectral photometrical oximeters

Abstract

Provided is a glucose amount calculation method which makes it possible to measure the amount of glucose accurately by statistically utilizing the intensity of each beam irradiated along an optical axis that penetrates through a human body.　A glucose amount estimation method according to the present invention comprises: a step for irradiate a measurement site in a human body with a first beam, a second beam and a third beam that have different wavelengths from one another and receiving the first beam, the second beam and the third beam that have passed through the measurement site by a light receiving element; and a step for estimating the amount of glucose from the light intensities of the first beam, the second beam and the third beam in accordance with a conversion equation. Furthermore, in the present invention, the conversion equation performs a multi-regression analysis, in which the intensities of a first beam, a second beam and a third beam which have different wavelengths from one another and have passed through a human body and the amount of glucose in collected blood are employed as a single actual measurement data set, a plurality of actual measurement data sets are acquired with respect to different glucose amounts, and the multi-regression analysis is performed on the basis of the plurality of actual measurement data sets.

IPC Classes  ?

• G01N 21/359 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light using near infrared light
• A61B 5/1455 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using optical sensors, e.g. spectral photometrical oximeters

Abstract

In the present invention, a low-molecular-weight compound 2,2,6,6-tetramtethyl-1-piperidinyloxyl (TEMPO) in the gas state is allowed to act on cells to suppress cell death associated with oxidative stress, thereby protecting tissue from tissue damage during the acute phase of ischemic disease.

IPC Classes  ?

• A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
• A61K 9/08 - Solutions
• A61K 9/20 - Pills, lozenges or tablets
• A61K 9/72 - Medicinal preparations characterised by special physical form for smoking or inhaling
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• A61P 21/02 - Muscle relaxants, e.g. for tetanus or cramps
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 39/06 - Free radical scavengers or antioxidants
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

[Problem] To provide an information processing device and program capable of supporting a diagnosis performed by a doctor, by automatically identifying a lesioned portion from the result of a positron emission tomography (PET) examination. [Solution] One aspect of the present invention provides an information processing device for identifying a lesioned portion on the basis of a positron emission tomography examination. The information processing device is provided with an image acquiring unit, and a lesion identifying unit. The image acquiring unit is configured to be capable of acquiring an image including an anatomical region imaged by a positron emission tomography device. The lesion identifying unit is configured to be capable of identifying a lesioned portion from a part of the image in which positron-emitting radionuclides are accumulated, on the basis of trained data obtained by machine learning.

IPC Classes  ?

• G01T 1/161 - Applications in the field of nuclear medicine, e.g. in vivo counting
• G06T 7/00 - Image analysis

Abstract

Provided is a motor control device with which, by employing a neural network structure, an output signal providing optimal efficiency can be derived directly, through training, and with which efficiency can be improved in real-time. A motor control device 1 controls a motor 6, and is provided with a neural network compensator 11 for deriving an output signal providing optimal efficiency, by inputting an input signal and repeating training by means of forward propagation and backpropagation, wherein the input signal is a motor current, a motor parameter, and torque, for example, and the output signal is a current command value or a current phase command value, and wherein the motor 6 is controlled on the basis of the output signal derived by the neural network compensator 11.

IPC Classes  ?

• H02P 21/14 - Estimation or adaptation of machine parameters, e.g. flux, current or voltage

Abstract

1 is an aliphatic hydrocarbon group having 10 to 26 carbon atoms.

IPC Classes  ?

• C07H 15/04 - Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of a saccharide radical
• C07H 7/02 - Acyclic radicals

Abstract

There is provided with a porphyrin compound represented by Formula (I) or a salt thereof; 6 alkyl group, and Rx is a substituent represented by General Formula. The porphyrin compound is useful as a cancer therapeutic agent, photosensitizer and fluorescent probe.

IPC Classes  ?

• C07H 17/02 - Heterocyclic radicals containing only nitrogen as ring hetero atoms
• A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation

Abstract

11-acidic glycoprotein (fAGP) is useful for the diagnosis of pancreatic cancer and malignant intraductal papillary mucinous carcinoma (IPMC), found is a novel biomarker for pancreatic cancer or malignant IPMC, particularly, a novel biomarker which is useful for rapidly diagnosing IPMC and improves a proper diagnosis rate of malignant IPMC and assists a conventional image diagnosis, by performing a preoperative diagnosis on whether an intraductal papillary mucinous neoplasm (IPMN) is benign or malignant.

IPC Classes  ?

• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

A blood measurement device (10) comprises: a light emitting unit (11) for emitting a light ray that passes through a site (18) being measured; a light receiving unit (19) for receiving the light ray that has passed through the site (18) being measured; an integrating sphere unit (14) disposed in a light path along which the light ray emitted from the light emitting unit (11) travels to the light receiving unit (19), the integrating sphere unit (14) having a reflective surface (26) formed therein for reflecting the light ray; a light inlet (23) that is an opening provided in the integrating sphere unit (14) and through which the light ray emitted from the light emitting unit (11) enters the inside of the integrating sphere unit (14); and a light outlet (16) that is an opening provided in the integrating sphere unit (14) and through which the light ray reflected by the reflective surface (26) of the integrating sphere unit (14) is emitted from the integrating sphere unit (14) toward the site being measured (18).

IPC Classes  ?

• G01N 33/483 - Physical analysis of biological material
• G01N 21/27 - ColourSpectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands using photo-electric detection
• A61B 5/1455 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using optical sensors, e.g. spectral photometrical oximeters

Abstract

The present invention addresses the problem of evaluating a neural action of a test substance at a high sensitivity, high quantitativeness particularly in a low concentration region and high reproducibility.　This problem can be solved by: a method that successively comprises (A) a step for culturing cultured nerve cells on the surface of a molded body which is formed of a norbornene-based polymer and at least the surface of which is hydrophilized, (B) a step for bringing the cultured nerve cells into contact with a test substance, (C) a step for fixing the cultured nerve cells, (D) a step for visualizing drebrin clusters of dendritic spines of the cultured nerve cells, and (E) a step for measuring the line density along the dendrites of the drebrin clusters, and determining that the test substance has a neural action when the line density increases or decreases compared with the line density of cultured nerve cells which are not contacted with the test substance; and a kit and a culture container to be used in this method.

IPC Classes  ?

• C12N 5/0793 - Neurons
• C12M 1/00 - Apparatus for enzymology or microbiology
• C12Q 1/06 - Quantitative determination
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals

Abstract

The present invention addresses the problem of providing a fiber sheet with which deterioration due to the oxidation action of a photocatalyst can be suppressed. Said problem is solved by a photocatalyst-supported copper fiber sheet which comprises: a copper fiber sheet; and a photocatalyst layer laminated on the copper fiber sheet.

IPC Classes  ?

• B01J 35/06 - Fabrics or filaments
• B01J 35/02 - Solids
• B32B 15/08 - Layered products essentially comprising metal comprising metal as the main or only constituent of a layer, next to another layer of a specific substance of synthetic resin
• B32B 15/14 - Layered products essentially comprising metal next to a fibrous or filamentary layer

Abstract

Provided is a polymer composite material or the like containing nanocellulose pieces that can be dispersed in a molten polymer. The polymer composite material contains: a matrix thermoplastic resin that serves as a base material; and flake-like nanocellulose pieces including cellulose nanofibers or cellulose nanocrystals obtained by binding, through covalent bonds or hydrogen bonds, molecules of a thermoplastic resin that is compatible with said matrix thermoplastic resin. The nanocellulose pieces are dispersed in the matrix thermoplastic resin.

IPC Classes  ?

• C08J 3/20 - Compounding polymers with additives, e.g. colouring
• C08L 1/02 - CelluloseModified cellulose
• C08L 23/02 - Compositions of homopolymers or copolymers of unsaturated aliphatic hydrocarbons having only one carbon-to-carbon double bondCompositions of derivatives of such polymers not modified by chemical after-treatment
• C08L 23/12 - Polypropene
• C08L 67/04 - Polyesters derived from hydroxy carboxylic acids, e.g. lactones
• C08L 101/00 - Compositions of unspecified macromolecular compounds

Abstract

In the present invention, a promoter on an AAV vector is changed to an Iba1 promoter, and a complementary sequence (miR-9T) of miR-9 and a complementary sequence (miR-129T) of miR-129 are combined. Since it is clearly demonstrated that using this vector makes it possible to express an exogenous gene effectively and specifically on microglia, an AAV vector is found which can express an exogenous gene effectively and specifically on microglia of the central nervous system.

IPC Classes  ?

• C12N 15/864 - Parvoviral vectors
• A61K 35/76 - VirusesSubviral particlesBacteriophages
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 25/00 - Drugs for disorders of the nervous system
• C12N 1/15 - Fungi Culture media therefor modified by introduction of foreign genetic material
• C12N 1/19 - YeastsCulture media therefor modified by introduction of foreign genetic material
• C12N 1/21 - BacteriaCulture media therefor modified by introduction of foreign genetic material
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 7/01 - Viruses, e.g. bacteriophages, modified by introduction of foreign genetic material
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 15/12 - Genes encoding animal proteins

Abstract

A method for detecting a gene mutation(s), the method comprising the steps of: hybridizing a single-stranded circular DNA and a primer with a target polynucleotide containing a first region and a second region adjacent to the 3′-side of the first region and containing a mutation; performing a nucleic acid amplification reaction by rolling circle amplification based on formation of a complex of the target polynucleotide, the primer, and the single-stranded circular DNA; and detecting amplified nucleic acid with a detection reagent. In this method, the single-stranded circular DNA contains a sequence complementary to the first region of the target polynucleotide, a primer-binding sequence adjacent to the 5′-side thereof, and preferably a sequence complementary to a detection reagent-binding sequence. The oligonucleotide primer contains a region having a sequence complementary to the second region of the target polynucleotide, and a region adjacent to the 3′-side thereof and having a sequence complementary to the primer-binding sequence of the single-stranded circular DNA.

IPC Classes  ?

• C12Q 1/6827 - Hybridisation assays for detection of mutation or polymorphism

Abstract

As therapy using the overexpression of endogenous genes becomes more and more important, there has been required, as a novel gene therapy tool, a small-sized system by which a potent gene can be activated and cloned into a viral vector. The present invention provides a system by which an endogenous gene can be overexpressed. More specifically, provided is a modified SunTag system by which a transcription-associated factor or a chromatin-associated factor and a demethylase are both introduced into a target gene with the use of dCas9-SunTag. According to this system, gene expression can be significantly activated compared to the introduction of the transcription-associated factor or the chromatin-associated factor alone or the demethylase alone. The introduction of the combination of a transcription-associated factor or a chromatin-associated factor with a demethylase using dCas9-SunTag can promote the expression of genes over a wide range, which makes this system applicable to broader targets.

IPC Classes  ?

• C12N 15/09 - Recombinant DNA-technology
• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 15/13 - Immunoglobulins
• C12N 15/53 - Oxidoreductases (1)
• C12N 15/54 - Transferases (2)
• C12N 15/62 - DNA sequences coding for fusion proteins
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression

Abstract

An imaging device 1 comprises: a variable focus lens 10; and an imaging sensor 15 that outputs a signal corresponding to light. The imaging sensor 15 includes: a photoelectric conversion unit PD that converts light to an electric charge; electric charge reading regions R1-R4; transfer control electrodes E1-E4; a gate control circuit 26 that sequentially applies control signals TG1-TG4 to the transfer control electrodes E1-E4 corresponding to the position of a focus P of the variable focus lens 10; and a reading circuit 27 that outputs a signal corresponding to an electric charge amount transferred to the electric charge reading regions R1-R4. The gate control circuit 26 repeats an operation of respectively outputting the control signals TG1-TG4 when the position of the focus P is in focus ranges BF1-BF4 within a frame period.

IPC Classes  ?

• G03B 15/00 - Special procedures for taking photographsApparatus therefor
• G02B 7/28 - Systems for automatic generation of focusing signals
• G03B 13/34 - Power focusing
• G03B 7/091 - Digital circuits
• H04N 5/225 - Television cameras
• H04N 5/369 - SSIS architecture; Circuitry associated therewith

Abstract

The present invention addresses the problem of providing a therapeutic agent for carcinomatous peritonitis. The present invention provides a therapeutic agent that is for carcinomatous peritonitis and that contains an antibody that recognizes a transferrin receptor.

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 35/00 - Antineoplastic agents
• A61P 35/04 - Antineoplastic agents specific for metastasis
• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• C12N 15/13 - Immunoglobulins
• C12P 21/08 - Monoclonal antibodies

Abstract

Provided is an electrode for a redox flow battery, the electrode being configured from a plate-form carbon electrode material in which uniform communication macro holes are formed in three-dimensional mesh form and there is no contact interface between carbon particles, and moreover being such that the average macro hole diameter of the carbon electrode material is within the range of 6-35 µm, the surface interval of a graphite crystallite (002) surface in the carbon electrode material is within the range of 0.33-0.40 nm, and the c-axis-direction crystallite size of the graphite crystallite is within the range of 0.9-8.5 nm.

IPC Classes  ?

• H01M 4/88 - Processes of manufacture
• H01M 4/96 - Carbon-based electrodes
• H01M 8/18 - Regenerative fuel cells, e.g. redox flow batteries or secondary fuel cells

Abstract

22, R1is a hydrogen atom, an alkoxy group having 1 to 4 carbon atoms, or an alkyl group having 1 to 10 carbon atoms which may be branched, R2is a hydrogen atom, halogen, an alkyl group having 1 to 10 carbon atoms which may be branched, a cycloalkyl group having 3 to 8 carbon atoms, or an alkoxy group having 1 to 4 carbon atoms, R3is a hydrogen atom, an alkyl group having 1 to 10 carbon atoms which may be branched, or an alkoxy group having 1 to 4 carbon atoms, and R4is a cycloalkyl group having 3 to 8 carbon atoms, a pyridyl group which may have a substituent, a pyrimidyl group which may have a substituent, a pyrazyl group which may have a substituent, a piperidyl group which may have a substituent, a piperazyl group which may have a substituent, a group represented by R41, a group represented by R42, a group represented by R43, or a group represented by R44.

IPC Classes  ?

• A61P 33/00 - Antiparasitic agents
• C07C 233/61 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by doubly-bound oxygen atoms
• C07D 211/62 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 213/81 - AmidesImides
• C07D 213/82 - AmidesImides in position 3
• C07D 295/185 - Radicals derived from carboxylic acids from aliphatic carboxylic acids
• C07D 239/28 - Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
• C07D 239/42 - One nitrogen atom
• C07D 241/20 - Nitrogen atoms
• C07D 241/24 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
• A61K 31/4402 - Non-condensed pyridinesHydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
• A61K 31/4409 - Non-condensed pyridinesHydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
• A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
• A61K 31/455 - Nicotinic acid, i.e. niacinDerivatives thereof, e.g. esters, amides
• A61K 31/4965 - Non-condensed pyrazines
• A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim

Abstract

Methods are provided for predicting a response to an anti-PD-1 antibody or anti-PD-L1 antibody therapy based on a new biomarker and for evaluating a malignancy of cancer. The method for predicting a response of a subject to an anti-PD-1 antibody or anti-PD-L1 antibody therapy includes measuring an expression level of LAT1 in a sample collected from a cancer tissue of the subject; and predicting a response of the subject to the anti-PD-1 antibody or anti-PD-L1 antibody therapy based on the expression level of LAT1. The method for evaluating a malignancy of cancer in a subject includes staining a sample collected from a cancer tissue of the subject with an anti-LAT1 antibody and an anti-PD-L1 antibody; and evaluating a malignancy of the cancer in the subject based on a presence or absence of a LAT1-positive and PD-L1-positive site.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 31/423 - Oxazoles condensed with carbocyclic rings
• A61P 35/00 - Antineoplastic agents
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The purpose of the present invention is to provide a volumetric display that is capable of rapid image presentation. The focal length of a resonance-type liquid lens 2 is periodically adjusted using resonance of a liquid. An image projection unit 1 projects an image toward the viewpoint position of a user via the resonance-type liquid lens 2. Furthermore, the image projection unit 1 projects an image toward the viewpoint position within a time that is less than 1/10 the cycle of fluctuation of the focal length. The image projection unit 1 is configured from an LED and a DMD, for example.

IPC Classes  ?

• G02B 30/54 - Optical systems or apparatus for producing three-dimensional [3D] effects, e.g. stereoscopic images the image being built up from image elements distributed over a 3D volume, e.g. voxels the 3D volume being generated by moving a 2D surface, e.g. by vibrating or rotating the 2D surface
• G02B 3/14 - Fluid-filled or evacuated lenses of variable focal length
• G02B 27/02 - Viewing or reading apparatus
• H04N 13/322 - Image reproducers for viewing without the aid of special glasses, i.e. using autostereoscopic displays using varifocal lenses or mirrors
• H04N 13/344 - Displays for viewing with the aid of special glasses or head-mounted displays [HMD] with head-mounted left-right displays
• H04N 13/365 - Image reproducers using digital micromirror devices [DMD]
• H04N 13/393 - Volumetric displays, i.e. systems where the image is built up from picture elements distributed through a volume the volume being generated by a moving, e.g. vibrating or rotating, surface
• H04N 13/398 - Synchronisation thereofControl thereof

Abstract

A guide mechanism for a conveyance cart according to the present invention, said mechanism comprising a permanent magnet, two electromagnet units, and a holding member. Each electromagnet unit comprises: a core including a first iron core section, a second iron core section, and a third iron core section; and coil sections wound around the respective iron core sections so as to change the magnetic flux density acting between each iron core section and a guide rail when electric power is supplied. The first iron core section is positioned below the guide rail and attracts the guide rail from below. The second iron core section is positioned at one end side in the width direction of the conveyance cart, and attracts the guide rail from the one end side in the width direction of the conveyance cart. The third iron core section is disposed at a predetermined spacing from the second iron core section in the width direction of the conveyance cart, and attracts the guide rail in a direction opposite to the direction of attraction by the second iron core section. Furthermore, the holding member holds the two electromagnet units and the permanent magnet in a state where the permanent magnet is sandwiched by the two electromagnet units, and sets the width direction of the conveyance cart in a longitudinal direction and is axially supported by a support member fixed to a link member of the conveyance cart.

IPC Classes  ?

• B61B 13/08 - Sliding or levitation systems
• B65G 54/02 - Non-mechanical conveyors not otherwise provided for electrostatic, electric, or magnetic
• B60L 13/04 - Magnetic suspension or levitation for vehicles

Abstract

The present invention addresses the problem of developing a reagent and a compound having a long phosphorescence lifetime for imaging of a low-oxygen cell or tissue, or measurement or quantification of the oxygen concentration in the low-oxygen cell or tissue. The present invention provides an oxygen concentration measurement reagent which contains a compound represented by general formula (I) or (II). (In the formulae, each of R1and R2independently represents a hydrogen atom or a hydrocarbon group having from 1 to 6 carbon atoms; and X- represents a counter anion.)

IPC Classes  ?

• C07D 417/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 491/16 - Peri-condensed systems
• C07F 15/00 - Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
• C09K 11/06 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing organic luminescent materials
• G01N 31/00 - Investigating or analysing non-biological materials by the use of the chemical methods specified in the subgroupsApparatus specially adapted for such methods
• G01N 21/78 - Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator producing a change of colour
• A61K 49/10 - Organic compounds
• G01N 33/483 - Physical analysis of biological material

Abstract

Provided is a substance capable of effectively suppressing cancer metastasis or a pharmaceutical composition that effectively acts on an inflammatory disease. The pharmaceutical composition is a pharmaceutical composition containing, as an active ingredient, an antibody or an antibody fragment thereof having antigen-binding activity for an S100A8/A9 heterodimer, and blocks interaction between S100A8/A9 and a group of receptors therefor, to thereby strongly suppress cancer metastasis both in vitro and in vivo, or alleviate inflammation. That is, the anti-S100A8/A9 antibody or the antibody fragment thereof can strongly suppress cancer metastasis or alleviate inflammation, by virtue of its blocking action on the interaction between S100A8/A9 and the group of receptors therefor.

IPC Classes  ?

• C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
• C07K 16/46 - Hybrid immunoglobulins
• C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 35/04 - Antineoplastic agents specific for metastasis
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

To provide a physiologically active agent for oral administration that contains a modified konjac flour as an active ingredient, said modified konjac flour comprising a water-soluble dietary fiber and an insoluble dietary fiber in a well-balanced manner, having good handling properties and high storage stability, being easily usable routinely and having a vegetable-like physiological activity. For this purpose, a modified konjac flour comprising 8-50 mass% of a water-soluble dietary fiber and 92-50 mass% of an insoluble dietary fiber is used as an active ingredient of a physiologically active agent for oral administration. The physiologically active agent for oral administration according to the present invention can be used as a blood glucose level elevation inhibitor.

IPC Classes  ?

• A61P 1/14 - Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
• A61P 3/00 - Drugs for disorders of the metabolism
• A61P 3/04 - AnorexiantsAntiobesity agents
• A61P 3/06 - Antihyperlipidemics
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61K 9/14 - Particulate form, e.g. powders
• A61K 36/888 - Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
• A61K 135/00 - Containing or obtained from stems, stalks, branches, twigs or shoots
• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A23L 33/21 - Addition of substantially indigestible substances, e.g. dietary fibres
• A61K 31/736 - Glucomannans or galactomannans, e.g locust bean gum, guar gum

Abstract

AABBB) of the light-receiving surface side. A reduced metal fine particle group (average particle diameter 20nm) was made to self-aggregate on a transparent polyester resin film, was halfway embedded, and was fixed. The resulting base material was repeatedly submerged in an electroless metal plating liquid, and metal particles were deposited on metal fine particle bodies. 10 microliters of a protein solution were dripped onto this nanostructure substrate and crystallized using a hanging drop vapor diffusion method.

IPC Classes  ?

• C07K 1/04 - General processes for the preparation of peptides on carriers
• C07K 1/14 - ExtractionSeparationPurification

Abstract

2y33; and y is an integer between 0 and 5.)

IPC Classes  ?

• G01N 21/64 - FluorescencePhosphorescence
• C07D 405/04 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 417/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
• G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers

Abstract

A sound insulating member includes a mass section and spring sections. The mass section is disposed so as to have a gap with respect to an outer panel which divides an internal space of a vehicle body and outside thereof, and includes at least a part which has a planar shaped form. The plurality of spring sections are disposed on the mass section at a side of the mass section facing an outer panel. Each of the spring sections has a hollow film member having airtightness and flexibility, and a gas sealed inside the film member. The film member has a first stepped section and a second stepped section that are formed in a stepped shape in an arrangement direction of the outer panel and the mass section.

IPC Classes  ?

• B60R 13/07 - Water drainage or guide means not integral with roof structure
• B60R 13/08 - Insulating elements, e.g. for sound insulation
• B60R 13/02 - Trim mouldingsLedgesWall linersRoof liners
• B62D 25/00 - Superstructure sub-unitsParts or details thereof not otherwise provided for

Abstract

The present invention addresses the problem of establishing a method for the direct, rapid and simple high-throughput evaluation of an NMDA receptor inhibition activity. An NMDA receptor inhibition activity can be evaluated with high throughput by a method comprising the following steps in this order: (A) bringing a substance of interest into contact with cultured neurons; (B) bringing the cultured neurons into contact with a glutamate solution; (C) immobilizing the cultured neurons; (D) visualizing drebrin clusters of dendritic spines of the cultured neurons; and (E) measuring the line density along the dendrites of the drebrin clusters, and determining that the substance of interest has an NMDA receptor inhibition activity when the line density is higher than the line density of the cultured neurons that are not contacted with the substance of interest.

IPC Classes  ?

• C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms
• G01N 33/15 - Medicinal preparations
• G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor

Abstract

A DNA methylation editing kit comprises: (1) a fusion protein of inactivated CRISPR-associated endonuclease Cas9 (dCas9) having no nuclease activity and a tag peptide array in which plural tag peptides are linked by linkers, or an RNA or DNA coding therefor; (2) a fusion protein(s) of a tag peptide-binding portion and a methylase or demethylase, or an RNA(s) or DNA(s) coding therefor; and (3) a guide RNA(s) (gRNA(s)) comprising a sequence complementary to a DNA sequence within 1 kb of a desired site of methylation or demethylation, or a DNA(s) expressing the gRNA(s).

IPC Classes  ?

• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
• C12N 15/90 - Stable introduction of foreign DNA into chromosome
• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 9/10 - Transferases (2.)
• C12N 15/09 - Recombinant DNA-technology
• C07K 16/44 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere
• C12N 1/00 - Microorganisms, e.g. protozoaCompositions thereofProcesses of propagating, maintaining or preserving microorganisms or compositions thereofProcesses of preparing or isolating a composition containing a microorganismCulture media therefor
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof

Abstract

This object surface processing method comprises: (a) a resin layer forming step of forming a resin layer containing a photosensitive resin on a substrate; (b) a primary irradiation step of irradiating light onto the resin layer from the surface on the side of the substrate which is opposite the side on which the resin layer has been formed; (c) an object disposition step of disposing, on the light-irradiated resin layer, an object having a non-flat surface, and (d) a secondary irradiation step of further irradiating light onto the resin layer from the surface on the side of the substrate which is opposite the side on which the resin layer has been formed, wherein the primary irradiation step is carried out under conditions wherein a portion of the resin layer is not cured, and the object disposition step is carried out in such a manner that the non-flat surface of the object faces the resin layer.

IPC Classes  ?

• B29C 59/16 - Surface shaping, e.g. embossingApparatus therefor by wave energy or particle radiation
• A61L 27/38 - Animal cells
• A61L 27/40 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material
• A61L 27/56 - Porous or cellular materials
• B32B 3/30 - Layered products comprising a layer with external or internal discontinuities or unevennesses, or a layer of non-planar shapeLayered products comprising a layer having particular features of form characterised by a particular shape of the outline of the cross-section of a continuous layerLayered products comprising a layer with external or internal discontinuities or unevennesses, or a layer of non-planar shapeLayered products comprising a layer having particular features of form characterised by a layer with cavities or internal voids characterised by a layer formed with recesses or projections, e.g. grooved, ribbed
• B32B 5/18 - Layered products characterised by the non-homogeneity or physical structure of a layer characterised by features of a layer containing foamed or specifically porous material
• C12M 3/00 - Tissue, human, animal or plant cell, or virus culture apparatus

Abstract

1λ12λ11λ22λ2ggg, and the number n of particles.

IPC Classes  ?

• G01N 15/02 - Investigating particle size or size distribution
• G01N 15/06 - Investigating concentration of particle suspensions

Abstract

A method of detecting a target molecule, the method comprising: forming a complex of a target molecule, a capture oligonucleotide, an oligonucleotide primer, and a single-stranded circular DNA; performing a nucleic acid amplification reaction by rolling circle amplification based on the formation of the complex; and detecting amplified nucleic acid; wherein the single-stranded circular DNA contains a first region, and a second region linked to the 3′-side of the first region, and preferably further contains a sequence complementary to a detection reagent-binding sequence; the primer contains a first aptamer sequence which binds to the target molecule, and a sequence which is linked to the 3′-side of the first aptamer sequence and is complementary to the first region of the single-stranded circular DNA; and the capture oligonucleotide contains a sequence complementary to the second region of the single-stranded circular DNA, and a second aptamer sequence which is linked to the 3′-side of the sequence complementary to the second region and binds to the target molecule.

IPC Classes  ?

• C12Q 1/6876 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
• C12N 15/115 - Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith
• C12Q 1/6844 - Nucleic acid amplification reactions
• C07D 277/66 - Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2

Abstract

In the present invention, a coating layer containing a fluoropolymer having a sulfonic acid group is laminated on at least one surface of a substrate layer containing a modified graphene oxide modified with a vinyl group-containing sulfonic acid. A first coating layer and a second coating layer may respectively be laminated on the two surfaces of the substrate layer. The sulfur content in the modified graphene oxide measured by element analysis may be 0.5-10 Atom%. The vinyl group-containing sulfonic acid may be vinylsulfonic acid or a metal salt thereof. By using the obtained laminate as a proton conductive electrolysis membrane in a solid fuel cell, the cell can be driven at room temperature and the proton conductivity and the output stability can be improved.

IPC Classes  ?

• B32B 9/00 - Layered products essentially comprising a particular substance not covered by groups
• B32B 27/30 - Layered products essentially comprising synthetic resin comprising vinyl resinLayered products essentially comprising synthetic resin comprising acrylic resin
• H01B 1/06 - Conductors or conductive bodies characterised by the conductive materialsSelection of materials as conductors mainly consisting of other non-metallic substances
• H01B 13/00 - Apparatus or processes specially adapted for manufacturing conductors or cables
• H01M 8/10 - Fuel cells with solid electrolytes
• H01M 8/1004 - Fuel cells with solid electrolytes characterised by membrane-electrode assemblies [MEA]
• H01M 8/1032 - Polymeric electrolyte materials characterised by the chemical structure of the main chain of the ion-conducting polymer having sulfur, e.g. sulfonated-polyethersulfones [S-PES]
• H01M 8/1053 - Polymer electrolyte composites, mixtures or blends consisting of layers of polymers with at least one layer being ionically conductive
• H01M 8/1069 - Polymeric electrolyte materials characterised by the manufacturing processes
• H01M 8/1072 - Polymeric electrolyte materials characterised by the manufacturing processes by chemical reactions, e.g. insitu polymerisation or insitu crosslinking

Abstract

The objective of the present invention is to provide a radiation measuring body and a radiation exposure dose measuring device which can be realized relatively inexpensively using a simple structure, and with which the exposure dose to which the crystalline lens of a subject, for example, is subjected can be measured rapidly and accurately. The radiation measuring body can be realized by forming a transparent dosimeter on a lens in the form of known spectacles, goggles, retrofitted sunglasses and the like, or protective glasses. The radiation exposure dose measuring device consists of a light shielding box in which the radiation measuring body is confined in order to block external light, and a computer. The computer includes a sequence control unit which controls a switch for blocking noise when the radiation measuring body is irradiated with exciting light and an amount of emitted light is measured.

IPC Classes  ?

• G01T 7/00 - Details of radiation-measuring instruments
• G01T 1/02 - Dosimeters
• A61B 6/10 - Safety means specially adapted therefor

Abstract

narrow: 0.4% or more and 15% or less.

IPC Classes  ?

• C01B 31/08 - Active carbon
• H01M 4/90 - Selection of catalytic material
• H01M 12/06 - Hybrid cellsManufacture thereof composed of a half-cell of the fuel-cell type and of a half-cell of the primary-cell type with one metallic and one gaseous electrode
• H01M 8/10 - Fuel cells with solid electrolytes
• B01J 21/18 - Carbon
• H01M 12/08 - Hybrid cellsManufacture thereof composed of a half-cell of a fuel-cell type and a half-cell of the secondary-cell type
• B01J 37/08 - Heat treatment
• H01M 4/587 - Carbonaceous material, e.g. graphite-intercalation compounds or CFx for inserting or intercalating light metals
• H01M 4/583 - Carbonaceous material, e.g. graphite-intercalation compounds or CFx
• H01M 4/133 - Electrodes based on carbonaceous material, e.g. graphite-intercalation compounds or CFx
• C01B 32/05 - Preparation or purification of carbon not covered by groups , , ,
• C01B 32/306 - Active carbon with molecular sieve properties
• H01M 8/1004 - Fuel cells with solid electrolytes characterised by membrane-electrode assemblies [MEA]
• H01M 8/1018 - Polymeric electrolyte materials

Abstract

2 to a culture vessel, and culturing the cells for 14 to 42 days.

IPC Classes  ?

• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
• C12N 5/0797 - Stem cellsProgenitor cells
• C12N 5/074 - Adult stem cells
• C12N 5/0735 - Embryonic stem cellsEmbryonic germ cells
• C12N 5/0793 - Neurons
• C12N 5/079 - Neural cells

Abstract

The present invention provides a novel nucleoside derivative or a salt thereof, a polynucleotide synthesis reagent, a method for producing a polynucleotide, a polynucleotide, and a method for producing a binding nucleic acid molecule. The nucleoside derivative or a salt thereof of the present invention is represented by the following chemical formula (1). 1 is a hydrogen atom or a straight-chain or branched, saturated or unsaturated hydrocarbon group having 2 to 10 carbon atoms.

IPC Classes  ?

• C07H 19/10 - Pyrimidine radicals with the saccharide radical being esterified by phosphoric or polyphosphoric acids
• C07H 19/20 - Purine radicals with the saccharide radical being esterified by phosphoric or polyphosphoric acids
• C12N 15/115 - Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C07H 1/00 - Processes for the preparation of sugar derivatives
• C07H 21/00 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
• C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
• C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical

Abstract

A method of producing a conditional knockout animal, and techniques related thereto, e.g., a method of efficiently producing a floxed animal, are provided. By introducing recombinase recognition sequences such as loxP into both ends of a target region on a chromosome at different timings, an animal having the pair of recombinase recognition sequences on the chromosome, such as a floxed animal, is produced.

IPC Classes  ?

• A01K 67/027 - New or modified breeds of vertebrates
• C12N 15/873 - Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos

Abstract

The purpose of the present invention is to provide an injectable sol into a body, suited for delivery through a catheter, and usable for tissue perforation closure, ulcer protection, or vascular embolization. Provided are a sol for tissue perforation closure, a sol for ulcer protection, and a sol for vascular embolization, each containing from 0.6 mass % to 3 mass % of a collagen, water, from 200 mM to 330 mM sodium chloride, and a buffer and having a pH from 6.0 to 9.0.

IPC Classes  ?

• A61L 24/10 - PolypeptidesProteins
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 47/02 - Inorganic compounds
• A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• A61K 47/42 - ProteinsPolypeptidesDegradation products thereofDerivatives thereof, e.g. albumin, gelatin or zein
• A61L 31/14 - Materials characterised by their function or physical properties
• A61K 9/06 - OintmentsBases therefor
• A61L 27/24 - Collagen
• A61L 31/04 - Macromolecular materials

Abstract

in vitroin vivoin vivo or ameliorates inflammation. Namely, the anti-S100A8/A9 antibody or an antibody fragment thereof has an effect of blocking the interaction between S100A8/A9 and the receptors thereof and thus can strongly inhibit cancer metastasis or ameliorate inflammation.

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 35/00 - Antineoplastic agents
• A61P 35/04 - Antineoplastic agents specific for metastasis
• C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
• C12N 15/13 - Immunoglobulins

Abstract

Object of the present invention is to provide a safe sol for submucosal local injection which gels and creates a mucosal elevation having a high retention rate of mucosal elevation height when locally injected into a digestive submucosa. Provided is a sol for submucosal local injection containing from 0.2 mass % to 1.2 mass % of a collagen, water, a buffer, and from 200 mM to 420 mM sodium chloride.

IPC Classes  ?

• A61L 31/04 - Macromolecular materials
• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61L 31/16 - Biologically active materials, e.g. therapeutic substances
• A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• A61K 9/06 - OintmentsBases therefor
• A61B 17/32 - Surgical cutting instruments
• A61L 31/14 - Materials characterised by their function or physical properties
• A61L 33/12 - Polypeptides, proteins or derivatives thereof
• A61B 17/28 - Surgical forceps
• A61K 47/42 - ProteinsPolypeptidesDegradation products thereofDerivatives thereof, e.g. albumin, gelatin or zein
• A61K 47/02 - Inorganic compounds

Abstract

A carbon catalyst has improved catalytic activity, and an electrode and a battery include the carbon catalyst. A carbon catalyst includes a metal and phosphorus atoms, wherein a ratio of a concentration (atomic %) of the phosphorus atoms exhibiting a peak having a peak top within a range of 132.5±0.3 eV and having a full width at half maximum of 2.0±0.5 eV, which is obtained by peak separation of a phosphorus atom P2p peak, with respect to a concentration (atomic %) of carbon atoms in X-ray photoelectron spectroscopic measurement is 0.0005 or more.

IPC Classes  ?

• H01M 4/90 - Selection of catalytic material
• B01J 21/18 - Carbon
• B01J 27/185 - PhosphorusCompounds thereof with iron group metals or platinum group metals
• B01J 31/02 - Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides

Abstract

The present invention addresses the problem of preparing a carbon-based composite for an oxygen reduction catalyst, the carbon-based composite comprising: a nanosheet-like graphene oxide or a reduction product thereof; and carbon quantum dots. The average particle diameter of the carbon quantum dots may be 20 nm or less. The nanosheet-like graphene oxide or the reduction product thereof, and the carbon quantum dots may be complexed in a uniformly mixed state. The carbon quantum dots may contain nitrogen atoms. The weight ratio of the nanosheet-like graphene oxide or the reduction product thereof to the carbon quantum dots may be 90/10 to 10/90 (the former/the latter). The carbon-based composite and a conductive aid may be combined to prepare a composite for a battery cathode catalyst layer. The conductive aid may be Ketjenblack. The carbon-based composite can be prepared simply and inexpensively, does not contain platinum, and can exhibit excellent oxygen reduction electrode characteristics.

IPC Classes  ?

• B01J 21/18 - Carbon
• B01J 35/02 - Solids
• B01J 37/10 - Heat treatment in the presence of water, e.g. steam
• B01J 37/16 - Reducing
• B01J 37/34 - Irradiation by, or application of, electric, magnetic or wave energy, e.g. ultrasonic waves
• C01B 32/15 - Nanosized carbon materials
• C01B 32/194 - After-treatment
• C01B 32/198 - Graphene oxide
• H01M 4/88 - Processes of manufacture
• H01M 4/90 - Selection of catalytic material
• H01M 4/96 - Carbon-based electrodes
• H01M 8/10 - Fuel cells with solid electrolytes

Abstract

The present invention provides a novel nucleoside derivative or a salt thereof, a polynucleotide synthesis reagent, a method for producing a polynucleotide, a polynucleotide, and a method for producing a binding nucleic acid molecule. The nucleoside derivative or a salt thereof of the present invention is represented by the following chemical formula (1): 1 is a hydrogen atom or a straight-chain or branched, saturated or unsaturated hydrocarbon group having 2 to 10 carbon atoms.

IPC Classes  ?

• C07H 19/10 - Pyrimidine radicals with the saccharide radical being esterified by phosphoric or polyphosphoric acids
• C07H 19/067 - Pyrimidine radicals with ribosyl as the saccharide radical
• C07H 19/073 - Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
• C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
• C12N 15/115 - Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith
• C07H 21/00 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Abstract

The present invention provides a novel molecule that can be used for detection of sIgA. The sIgA-binding nucleic acid molecule of the present invention is characterized in that it binds to secretory immunoglobulin A (sIgA) with a dissociation constant of 37.7 nM or less, and preferably includes a polynucleotide consisting of any of base sequences of SEQ ID NOs: 1 to 12 or a partial sequence thereof, for example. According to the sIgA-binding nucleic acid molecule of the present invention, it is possible to detect sIgA in saliva.

IPC Classes  ?

• C12N 15/115 - Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• C12N 15/09 - Recombinant DNA-technology

Abstract

The present invention provides a novel nucleoside derivative or a salt thereof, a polynucleotide synthesis reagent, a method for producing a polynucleotide, a polynucleotide, and a method for producing a binding nucleic acid molecule. The nucleoside derivative or a salt thereof of the present invention is represented by the following chemical formula (1): 1 is a hydrogen atom or a straight-chain or branched, saturated or unsaturated hydrocarbon group having 2 to 10 carbon atoms.

IPC Classes  ?

• C07H 19/02 - Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radicalNucleosidesMononucleotidesAnhydro derivatives thereof sharing nitrogen
• C07H 19/04 - Heterocyclic radicals containing only nitrogen as ring hetero atom
• C07H 19/14 - Pyrrolo-pyrimidine radicals
• C07H 19/20 - Purine radicals with the saccharide radical being esterified by phosphoric or polyphosphoric acids
• C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
• C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
• C12N 15/115 - Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith
• C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies

Abstract

Provided are an objective pain sensation measurement device and an objective pain sensation measurement method which are capable of detecting pain sensation with high accuracy, which is caused by a certain physical stimulus to a subject, without being influenced by the subjectivity of the subject, and of measuring a degree of the pain sensation. Before the physical stimulus is applied to the subject, a moving average value of skin conductance is stored in advance in a skin conductance initial value memory as a skin conductance initial value. In addition, a change rate of the skin conductance is calculated on the basis of the skin conductance initial value. The pain sensation based on the physical stimulus can be specifically detected and objective measurement of the pain sensation can be implemented by measuring the presence or absence of pain sensation, or the degree of the pain sensation by using the change rate of the skin conductance.

IPC Classes  ?

• A61B 5/05 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves
• A61B 10/00 - Instruments for taking body samples for diagnostic purposesOther methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determinationThroat striking implements

Abstract

broad, is 0.374 nm or more.

IPC Classes  ?

• H01M 4/96 - Carbon-based electrodes
• C01B 32/05 - Preparation or purification of carbon not covered by groups , , ,
• B01J 23/80 - Catalysts comprising metals or metal oxides or hydroxides, not provided for in group of the iron group metals or copper combined with metals, oxides or hydroxides provided for in groups with zinc, cadmium or mercury
• H01M 4/90 - Selection of catalytic material
• H01M 4/86 - Inert electrodes with catalytic activity, e.g. for fuel cells
• H01M 8/10 - Fuel cells with solid electrolytes

Abstract

A simple production process is provided of a perfluoroalkyl compound that uses monohydroperfluoroalkane as a starting material, the perfluoroalkyl compound being an important intermediate of organic electronic materials, medicine, agricultural chemicals, functional polymer materials and the like. With monohydroperfluoroalkane is reacted a base and then a carbonyl compound to produce an alcohol having a perfluoroalkyl group. For example, potassium hydroxide is made to interact with trifluoromethane, and a reaction with a carbonyl compound is induced to produce an alcohol having a trifluoromethyl group.

IPC Classes  ?

• C07C 29/38 - Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring increasing the number of carbon atoms by reactions with formation of hydroxy groups, which may occur via intermediates being derivatives of hydroxy groups, e.g. O-metal by reaction with aldehydes or ketones
• C07C 31/125 - Monohydroxylic acyclic alcohols containing five to twenty-two carbon atoms
• C07C 33/46 - Halogenated unsaturated alcohols containing only six-membered aromatic rings as cyclic part
• C07C 35/48 - Halogenated derivatives
• C07C 43/23 - Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
• C07C 209/68 - Preparation of compounds containing amino groups bound to a carbon skeleton from amines, by reactions not involving amino groups, e.g. reduction of unsaturated amines, aromatisation, or substitution of the carbon skeleton
• C07C 211/48 - N-alkylated amines
• C07C 231/12 - Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
• C07C 233/15 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
• C07C 41/30 - Preparation of ethers by reactions not forming ether-oxygen bonds by increasing the number of carbon atoms, e.g. by oligomerisation
• C07C 209/78 - Preparation of compounds containing amino groups bound to a carbon skeleton from amines, by reactions not involving amino groups, e.g. reduction of unsaturated amines, aromatisation, or substitution of the carbon skeleton from carbonyl compounds, e.g. from formaldehyde, and amines having amino groups bound to carbon atoms of six-membered aromatic rings, with formation of methylene-diarylamines

Abstract

The purpose of the present invention is to provide a method for predicting the efficacy of anti-PD-1 antibody or anti-PD-L1 antibody therapy and a method for evaluating the grade of a cancer that are based on a novel biomarker. This method for predicting the efficacy of anti-PD-1 antibody or anti-PD-L1 antibody therapy on a subject includes a step for measuring the LAT1 expression level in a sample collected from the cancerous tissue of the subject, and a step for predicting the efficacy of anti-PD-1 antibody or anti-PD-L1 antibody therapy on the subject on the basis of the LAT1 expression level. The method for evaluating the grade of a cancer in a subject includes a step for using anti-LAT1 antibodies and anti-PD-L1 antibodies to stain a sample collected from the cancerous tissue of the subject, and a step for evaluating the grade of the cancer in the subject on the basis of the presence or absence of LAT1-positive and PD-L1-positive sites.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

[Problem] To provide a polymer/nanoparticle composite hydrogel having outstanding mechanical properties and elongation properties, and which can be produced with general-purpose materials which can be obtained easily in industrial terms. [Solution] A self-supporting hydrogel containing a silicate (A), a polyalkylene glycol (B) and a silicate dispersant (C), the hydrogel being characterized in that the polyalkylene glycol (B) has a weight-average molecular weight, number-average molecular weight or viscosity-average molecular weight of 500,000 to 20,000,000, and with respect to 100% by mass of the hydrogel, the polyalkylene glycol (B) accounts for more than 2% by mass but not more than 20% by mass. A method for producing the self-supporting hydrogel is also provided.

IPC Classes  ?

• C08L 71/02 - Polyalkylene oxides
• B01J 13/00 - Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided forMaking microcapsules or microballoons
• C08J 3/075 - Macromolecular gels
• C08K 3/34 - Silicon-containing compounds
• C08K 5/52 - Phosphorus bound to oxygen bound to oxygen only

Abstract

An RNA detection kit comprising: (i) a single-stranded circular DNA template containing: a sequence of 10 to 30 bases complementary to a first portion of a target RNA; a primer-binding sequence of 7 to 8 bases adjacent to 5′-side thereof; and a sequence complementary to a detection reagent-binding sequence such as a guanine quadruplex-forming sequence; (ii) an oligonucleotide primer containing: a sequence of 8 to 15 bases complementary to a second portion adjacent to the 3′-side of the first portion of the target RNA; and a sequence of 7 to 8 bases adjacent to 3′-side thereof and complementary to the primer-binding sequence of the single-stranded circular DNA template; and (iii) a detection reagent such as a guanine quadruplex-binding reagent; is provided.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• C12Q 1/6876 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
• C12Q 1/6844 - Nucleic acid amplification reactions

Abstract

A DNA methylation editing kit comprises: (1) a fusion protein of inactivated CRISPR-associated endonuclease Cas9 (dCas9) having no nuclease activity and a tag peptide array in which plural tag peptides are linked by linkers, or an RNA or DNA coding therefor; (2) a fusion protein(s) of a tag peptide-binding portion and a methylase or demethylase, or an RNA(s) or DNA(s) coding therefor; and (3) a guide RNA(s) (gRNA(s)) comprising a sequence complementary to a DNA sequence within 1 kb of a desired site of methylation or demethylation, or a DNA(s) expressing the gRNA(s).

IPC Classes  ?

• C12N 9/00 - Enzymes, e.g. ligases (6.)ProenzymesCompositions thereofProcesses for preparing, activating, inhibiting, separating, or purifying enzymes
• C12N 15/90 - Stable introduction of foreign DNA into chromosome
• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 9/10 - Transferases (2.)
• C12N 15/09 - Recombinant DNA-technology
• C07K 16/44 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere
• C12N 1/00 - Microorganisms, e.g. protozoaCompositions thereofProcesses of propagating, maintaining or preserving microorganisms or compositions thereofProcesses of preparing or isolating a composition containing a microorganismCulture media therefor
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof

Abstract

The purpose of the present invention is to provide a method for conveniently and industrially producing at low cost, a compound having a polyene skeleton and containing hydrogen and fluorine and/or chlorine. Provided is a method for producing a halogenated diene represented by formula (1), A1A2C=CA3-CA4=CA5A6 [in the formula, A1, A2, A5, and A6 independently represent hydrogen, fluorine or chlorine, a C1-3 (perfluoro) alkyl group or (perfluoro) alkenyl group, A3 and A4 independently represent hydrogen, fluorine or chlorine, at least one among A1-A6 represents hydrogen, and at least one among A1-A6 represents fluorine or chlorine], the method comprising a step for subjecting identical or different halogenated olefins represented by formula (2), A7A8C=CA9X [in the formula, A7 and A8 independently represent hydrogen, fluorine or chlorine, a C1-3 (perfluoro) alkyl group or (perfluoro) alkenyl group, A9 independently represents hydrogen, fluorine or chlorine, and X represents bromine or iodine], to a coupling reaction in the presence of a zero-valent metal.

IPC Classes  ?

• C07C 17/269 - Preparation of halogenated hydrocarbons by reactions involving an increase in the number of carbon atoms in the skeleton by condensation reactions of only halogenated hydrocarbons
• C07C 21/20 - Halogenated butadienes
• C07B 61/00 - Other general methods

Abstract

An effective amount of botulinum toxin type B is administered to a subject in need thereof for treating Raynaud's phenomenon. Botulinum toxin type B may be in a form of an injection, and may be locally administered to a disease affected site, in a dose of 200 to 400 units per disease affected site.

IPC Classes  ?

• A61K 38/48 - Hydrolases (3) acting on peptide bonds (3.4)
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 9/00 - Drugs for disorders of the cardiovascular system

Abstract

2 or more at a hydrogen pressure of 10 MPa.

IPC Classes  ?

• C01B 3/00 - HydrogenGaseous mixtures containing hydrogenSeparation of hydrogen from mixtures containing itPurification of hydrogen
• B01J 20/20 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising inorganic material comprising free carbonSolid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising inorganic material comprising carbon obtained by carbonising processes
• B01J 20/28 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof characterised by their form or physical properties
• B01J 20/30 - Processes for preparing, regenerating or reactivating
• C01B 32/05 - Preparation or purification of carbon not covered by groups , , ,
• C01B 32/318 - Preparation characterised by the starting materials

Abstract

To provide a method for joining metal members, in which joining can be performed at relatively lower temperature, and deformation caused when joining the metal members can be reduced. The present invention includes a step of joining a plurality of metal members with a sheet sandwiched between the joining surfaces of the plurality of metal members, wherein the sheet is obtained by forming an organic acid metal salt film on the surface of a metal sheet; wherein aluminum or an aluminum alloy is used as the metal members, and a sheet made of any one of zinc, copper and magnesium is used as the metal sheet.

IPC Classes  ?

• B23K 31/02 - Processes relevant to this subclass, specially adapted for particular articles or purposes, but not covered by any single one of main groups relating to soldering or welding
• B23K 20/16 - Non-electric welding by applying impact or other pressure, with or without the application of heat, e.g. cladding or plating with interposition of special material to facilitate connection of the parts, e.g. material for absorbing or producing gas
• B23K 1/20 - Preliminary treatment of work or areas to be soldered, e.g. in respect of a galvanic coating
• B23K 20/02 - Non-electric welding by applying impact or other pressure, with or without the application of heat, e.g. cladding or plating by means of a press
• B23K 20/233 - Non-electric welding by applying impact or other pressure, with or without the application of heat, e.g. cladding or plating taking account of the properties of the materials to be welded without ferrous layer
• B23K 20/24 - Preliminary treatment
• B23K 103/10 - Aluminium or alloys thereof
• B23K 103/20 - Ferrous alloys and aluminium or alloys thereof
• B23K 103/12 - Copper or alloys thereof

Abstract

A method for detecting a target molecule, wherein: the method includes a step for forming a complex of a target molecule, a capture oligonucleotide, an oligonucleotide primer, and a single-stranded circular DNA, a step for conducting a nucleic acid amplification reaction based on complex formation by rolling circle amplification, and a step for detecting the amplified nucleic acid; the single-stranded circular DNA includes a first region and a second region linked to the 3' side of the first region, and preferably also a sequence complementary to the detection-reagent-binding sequence; the primer includes a first aptamer sequence that binds to the target molecule and a sequence that is complementary to the first region of the single-stranded circular DNA and is linked to the 3' side of the first aptamer sequence; and the capture oligonucleotide includes a sequence complementary to the second region of the single-stranded circular DNA and a second aptamer sequence that binds to the target molecule and is linked to the 3' side of the sequence.

IPC Classes  ?

• C12Q 1/6844 - Nucleic acid amplification reactions
• C12N 15/115 - Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith
• C12Q 1/6876 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes